| Institution: | GlaxoSmithKline, LLC | Auftraggeber: | Analysis Group, Inc. |
| Titel der NIS: | A real-world study to assess treatment patterns and outcomes of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy in the United Kingdom, Italy, and Germany | ||
| Ziel der NIS: | The purpose of this study to generate detailed real-world data on second line treatments for multiple myeloma and to analyze treatment patterns, and economic and clinical burden of multiple myeloma among patients age 18 years and older. The findings will contribute to the quantification of the complex treatment landscape for multiple myeloma. |
||
| Ort der Durchführung: | multinational | ||
| Patientenanzahl insgesamt: | 440 | Anzahl Ärzte insgesamt: | 220 |
| Patientenanzahl in Deutschland: | 120 | Ärzte in Deutschland: | 60 |
| Anzeige am: | 14.11.2023 | Geplanter Beginn: | 01.11.2023 | Geplantes Ende: | 01.11.2024 |
| Arzneimittelbezeichnung | INN | Zulassungs-Nr. | ATC-Code | Substanzklasse |
|---|---|---|---|---|
| Blenrep | Belantamab mafodotin | PLGB 19494/0296 | L01FX15 | Antineoplastic agents, monoclonal antibodies and antibody drug conjugates |
| THALOMID | Thalidomide | PLGB 15105/0178 | L04AX02 | Immunosuppressants; Other immunosuppressants. |
| VELCADE | Bortezomib | PLGB00242/0707 | L01XX32 | Antineoplastic agents; other antineoplastic agents |
| KYPROLIS | Carfilzomib | PLGB 13832/0023 PLGB 13832/0024 PLGB 13832/0025 | L01XX45 | Antineoplastic agents, other antineoplastic agents |
| NINLARO | Ixazomib | PLGB 15475/0059 PLGB 15475/0060 PLGB 15475/0061 | L01XG03 | Antineoplastic agents, other antineoplastic agents |
| Art des Dokuments | |
|---|---|
| Beobachtungsplan, NIS 745 | pdf 414KB |
